Global human microbiome therapeutics market size to cross USD 1,544 million by 2027

The report on ‘global human microbiome therapeutics market’ showcases thorough assessment of the industry with regards to important aspects such as major growth drivers, challenges & threats, and key opportunities.

Selbyville, Delaware, Oct. 21, 2020 (GLOBE NEWSWIRE) -- As per industry experts, global human microbiome therapeutics market is estimated to record strong CAGR, while accumulating USD 1,544.6 million by the year 2027. Rising emphasis on microbiome enabled early detection of diseases, high prevalence of ailments due to dysbiosis, increasing government investment in microbiome projects, and surging organization collaborations are the major factors impelling worldwide human microbiome therapeutics industry outlook.

As per the given report, global human microbiome therapeutics market is classified into segments based on product spectrum, therapeutic area, indication type, and approach followed. In-depth scrutiny of regional markets is also carried out, while studying the competitive hierarchy. Strategies applied by industry behemoths, alongside their business profile and product portfolio are also presented in the report.  
For the uninitiated, microbiome are microbial genomes that reside in the gut of human body. It plays vital role in endocrine system, digestion, immune system, mental health, and act as defense against pathogens. Any disruption in body equilibrium can lead to brain malfunction and metabolic disorders, hence indicating the importance of microbiome and related therapeutics.

Request Sample copy of this Report @

Dearth of therapeutics for women health and rare diseases, in tandem with surge in instances of infection ailments are stimulating global human microbiome therapeutics market dynamics. Further, numerous R&D projects, as well as reported side-effects related to existing drugs, and applications in personalized drug & nutrition will provide impetus for industry expansion.

However, complications with microbiome, along with uncertainties regarding microbial interactions with currently available drugs and their side effects are major challenges restraining global human microbiome therapeutics industry scope. 

Highlighting product spectrum

According to report findings, probiotics segment led human microbiome therapeutics industry share in 2019 and is poised to growth further. High nutritional benefits, rising research & development activities for microbiome-based probiotics, along with restrictions on usage of antibiotic growth promoters in food products in the European Union are drawing traction towards probiotics.  

Elaborating on therapeutic area

Worldwide microbiome therapeutics market size from infectious disease segment is expected to witness the highest growth rate over the forecast period, owing to increasing prevalence of microbial dysbiosis based infections, and widespread usage of antibiotics. Surging clinical trials in microbiome-based therapies for infectious disorders will create growth prospects for industry partakers.

Overview of indication type

Credible sources cite that diabetes indication is predicted to greatly influence global human microbiome therapeutics market dynamics over the forecast period. Positive clinical evidence for diabetes treatment using live biotherapeutics, and long pipeline of products will boost the segmental share.

To access a sample copy or view this report in detail along with the table of contents, please click the link below:

Analyzing approach segment

Small molecule therapies segment of global human microbiome therapeutics industry is slated to register momentous growth rate through 2027, owing to massive number of drugs in the pipeline.

Regional scrutiny

North America human microbiome therapeutics market trends over 2020-2027 are primarily driven by inflowing government funding towards microbiome projects, increasing collaboration among companies and academies, in consort with presence of small start-up dedicated to microbiome.

Global Human Microbiome Therapeutics Market Product Spectrum (Revenue, USD Million, 2016-2027)

  • Probiotics
  • Medical Foods
  • Prescription Drugs
  • Prebiotics

Global Human Microbiome Therapeutics Market by Therapeutic Area (Revenue, USD Million, 2016-2027)

  • Dermatological Disorders
  • Dental Disorders
  • Metabolic Disorders
  • Autoimmune Disorders
  • Digestive & Gastrointestinal Disorders
  • Infectious Disease
  • Oncology
  • Others

Global Human Microbiome Therapeutics Market by Indication Type (Revenue, USD Million, 2016-2027)

  • Clostridium Difficile Infection
  • Lung Cancer
  • Atopic Dermatitis
  • Colorectal Cancer
  • Diabetes
  • Acne Vulgaris
  • Lactose Intolerance
  • Inflammatory Bowel Disease (IBD)
  • Coeliac Disease
  • Non-Alcoholic Steatohepatitis (NASH)
  • Obesity

Global Human Microbiome Therapeutics Market by Approach (Revenue, USD Million, 2016-2027)

  • Microbial Ecosystems
  • Genetically Modified Single Strain Bacteria
  • Single Strain Whole Bacteria
  • Small Molecule Therapies
  • Phage Cocktail
  • Microbial Consortia

Global Human Microbiome Therapeutics Market Regional Outlook (Revenue, USD Million, 2016-2027)

North America

  • Canada
  • U.S.


  • Germany
  • France
  • Austria
  • UK
  • Spain
  • Netherlands
  • Italy

Asia Pacific

  • Malaysia
  • India
  • Japan
  • Australia
  • China
  • South Korea

Latin America

  • Mexico
  • Argentina
  • Brazil

Middle East & Africa

  • Saudi Arabia
  • UAE
  • South Africa
  • Israel

Global Human Microbiome Therapeutics Market Competitive Landscape (Revenue, USD Million, 2016-2027)

  • Embion Technologies SA
  • Enterome Bioscience
  • Igen Biolab Group AG
  • Evelo Biosciences
  • Ferring Pharmaceuticals
  • Finch Therapeutics Group Inc.
  • Vedanta Biosciences Inc.
  • 5QBD-Biotech
  • 4D Pharma plc
  • Seres Therapeutics
  • GNUbiotics Sciences SA

Table of Content:

1. Introduction

1.1. Report Description

1.1.1. Objectives of the Study

1.1.2. Market Scope

1.1.3. Assumptions

1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview

3.1.1. Data Mining

3.2. Data Sources

3.2.1. Primary Sources

3.2.2. Secondary Sources

4. Human Microbiome Therapeutics Market Insights

4.1. Human Microbiome Therapeutics - Industry snapshot

4.2. Human Microbiome Therapeutics Market Dynamics

4.3. Porter's Five Forces Analysis

4.4. PESTLE Analysis

4.5. Human Microbiome Therapeutics Market Industry trends

5. Human Microbiome Therapeutics Market Assessment by Product

5.1. Key Findings

5.2. Introduction

5.3. Probiotics

5.4. Prebiotics

5.5. Medical Foods

5.6. Prescription Drugs

6. Global Human Microbiome Therapeutics Market, by Therapeutic Area

6.1. Key Findings

6.2. Introduction

6.3. Autoimmune Disorders

6.4. Dental Disorders

6.5. Digestive and Gastrointestinal Disorders

6.6. Dermatological Disorders

6.7. Infectious Disease

6.8. Metabolic Disorders

6.9. Oncology

7. Global Human Microbiome Therapeutics Market, by Indication

7.1. Key Findings

7.2. Introduction

7.3. Acne Vulgaris

7.4. Atopic Dermatitis

7.5. Clostridium difficile Infection

7.6. Colorectal Cancer

7.7. Diabetes

7.8. Inflammatory Bowel Disease (IBD)

7.9. Lactose Intolerance

7.10. Lung Cancer

8. Human Microbiome Therapeutics Market Assessment by Approach

8.1. Key Findings

8.2. Introduction

8.2.1. Global Human Microbiome Therapeutics Market, By Approach, 2015 - 2026 (USD Million)

8.3. Small Molecule Therapies

8.3.1. Global Human Microbiome Therapeutics Market, by Small Molecule Therapies, by Region, 2016- 2027 (USD Million)

8.4. Single Strain Whole Bacteria

8.4.1. Global Human Microbiome Therapeutics Market, by Single Strain Whole Bacteria, by Region, 2016- 2027 (USD Million)

8.5. Microbial Consortia

8.5.1. Global Human Microbiome Therapeutics Market, by Microbial Consortia, by Region, 2016- 2027 (USD Million)

9. Human Microbiome Therapeutics Market Assessment by Geography

Related Report:

Pneumonia Therapeutics Market Size, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026

Pneumonia Therapeutics Market size grow at a CAGR of 7.6% from 2020 to 2026, as per new research report. Pneumonia is widely referred to as a disease condition that affects the alveoli of the lungs. Pneumonia is caused by fungi, bacteria or viruses and accounts for 5% of deaths among children below 5 years of age. Prevalence of pneumonia is significantly high in paediatric population of African countries. However, lack of accessibility to pneumonia therapeutics and treatment facilities has kept mortality rate higher in African countries. Antiviral drugs market segment will witness around 7.5% CAGR during the forecast period. Viral pneumonia spreads through fluid present in the air droplets after an individual coughs or sneezes. These fluids enter into the body through mouth or nose.

About US:

Market Study Report, LLC. is a hub for market intelligence products and services.

We streamline the purchase of your market research reports and services through a single integrated platform by bringing all the major publishers and their services at one place.

Our customers partner with Market Study Report, LLC. to ease their search and evaluation of market intelligence products and services and in turn focus on their company's core activities.

If you are looking for research reports on global or regional markets, competitive information, emerging markets and trends or just looking to stay on top of the curve then Market Study Report, LLC. is the platform that can help you in achieving any of these objectives.


Contact Data